Effects of constant intravenous infusion of detomidine alone or combined with butorphanol or methadone for standing sedation in horses: A randomized clinical trial.

This piece of research evaluated the sedation degree and cardiopulmonary effects in horses when a constant infusion of detomidine, a sedative, was used alone or paired with pain relievers butorphanol or methadone. The research demonstrated that the addition of opioids resulted in less detomidine being needed and significantly reduced its requirement.

Research Overview

• This study aimed at understanding the effects of administering detomidine, a sedative, alone or in combination with opioids like butorphanol or methadone for sedating horses during dental occlusal adjustment process. The research also sought to establish the amount of detomidine that could be saved in the process.
• The procedures were conducted in a controlled environment where 24 healthy adult horses were given the sedatives in different combinations and their reactions were then tracked and documented. The different combinations were grouped into detomidine (DT), detomidine-butorphanol (DB) or detomidine-methadone (DM).

Administration of Treatment

• The detomidine treatment involved an intravenous dose (20 μg/kg) followed by a constant rate infusion (CRI) at 20 μg/kg/h.
• In the case of detomidine-butorphanol treatment, the horses received boluses of detomidine (10 μg/kg) and butorphanol (0.02 mg/kg). The CRI was set at 10 μg/kg/h and 0.03 mg/kg/h respectively.
• For the detomidine-methadone treatment, horses received detomidine (10 μg/kg) and methadone (0.2 mg/kg) boluses with a CRI at 10 μg/kg/h and 0.05 mg/kg/h respectively.
• If more sedation was needed, an additional dose of detomidine was given without changing the rate of the constant infusion.

Research Findings

• The sedation effect was monitored for up to 12 hours after the procedure was completed. The respiration rate, heart rate, systolic blood pressure, temperature, and gastrointestinal motility were recorded. Other factors like the depth of sedation and the requirement of additional detomidine were also considered.
• All treatments were found to reduce heart rate and gastrointestinal motility. The combination of detomidine and methadone also resulted in decreased respiration rate.
• In the scenarios where further sedation was needed, fewer instances were recorded in the detomidine-methadone group than the other two groups.
• The total consumption of detomidine was significantly lower in the detomidine-methadone (10.6 ± 2.32 μg/kg/h) and detomidine-butorphanol (13.6 ± 4.58 μg/kg/h) groups when compared to detomidine alone (22.4 ± 4.1 μg/kg/h).
• The addition of opioids showed a detomidine-sparing effect by significantly reducing the requirement of detomidine for sedation.